Esketamine vs Ketamine: What's the Difference?
- Sophroneo Psychiatry
- 1 day ago
- 5 min read
Ketamine and esketamine sound almost interchangeable, but the difference is not a small technical detail. For someone exploring newer depression treatments, it can affect insurance coverage, treatment setting, monitoring requirements, cost, and how much formal trial data supports the option.
If you are comparing options for depression treatment, especially after several medications have not helped enough, this guide explains what separates Spravato esketamine from IV ketamine. At Sophroneo Behavioral Health & TMS, we help patients look at these choices through the lens of diagnosis, safety, history, insurance, and the full treatment plan, not hype.
This article is educational and is not a substitute for diagnosis, medication advice, or a personalized treatment plan. If you feel unsafe, have thoughts of suicide, or may harm yourself, call or text 988 in the U.S. or go to the nearest emergency department.
What is esketamine?
Ketamine is a molecule with two mirror-image forms, often described as the right-handed and left-handed versions of the same compound. Esketamine is the S-enantiomer of ketamine. In depression care, esketamine is best known by the brand name Spravato.
Spravato is given as a nasal spray in a certified clinical setting, where the patient self-administers the dose under direct supervision and is monitored afterward. That supervised structure matters because esketamine can cause sedation, dissociation, temporary blood pressure changes, and impaired driving ability on treatment days.
Because Spravato has a formal approval pathway for certain people with treatment-resistant depression, many patients start their research with Sophroneo's Spravato specialist page before comparing it with other options.
What is IV ketamine?
IV ketamine usually refers to racemic ketamine, meaning it contains both major enantiomers of ketamine together. It is delivered intravenously, often over a monitored infusion session. Ketamine has been used in medicine for decades, including as an anesthetic, and clinicians later began studying its antidepressant effects.
The key distinction is that IV ketamine for depression is generally considered off-label. Off-label use does not automatically mean inappropriate or ineffective. It does mean the treatment does not have the same depression-specific FDA approval pathway as Spravato, and that can affect insurance coverage and access.
For readers comparing clinic-based ketamine options, Sophroneo's overview of ketamine treatment for depression can help place this conversation inside a broader depression-care plan.
Esketamine vs ketamine: evidence, insurance, and setting
The evidence base is different, not simply "better" or "worse" in every situation. Spravato esketamine went through a formal drug-approval process for specific depression indications, which is why insurance coverage is often more realistic for qualifying patients. IV ketamine has a substantial clinical and research history, but for depression it usually lacks the same insurance pathway.
For many patients, the practical differences look like this:
• Spravato esketamine is administered as a supervised nasal spray in a certified setting.
• IV ketamine is administered through an infusion and is often paid out of pocket.
• Spravato may be covered for qualifying treatment-resistant depression after prior authorization.
• IV ketamine may allow a different dosing and delivery approach, but coverage is less predictable.
• Both require careful screening, monitoring, and follow-up with a clinician familiar with depression care.
This is why a decision should not be based on a single factor. The right option may depend on your diagnosis, medication history, response to prior antidepressants, safety concerns, medical conditions, insurance plan, and comfort with the treatment setting.
How Sophroneo helps you compare esketamine vs ketamine
At Sophroneo, the conversation usually starts with the person, not the treatment menu. A psychiatrist should first clarify whether the symptoms fit major depressive disorder, treatment-resistant depression, bipolar depression, trauma-related depression, ADHD-related impairment, medication side effects, sleep disruption, substance use, or another overlapping issue.
That broader view matters because some people need medication optimization, psychotherapy support, sleep treatment, safety planning, or a different diagnosis before choosing a ketamine-based treatment. Others may benefit from comparing Spravato with NeuroStar TMS, learning how TMS works, or reviewing whether TMS is a fit before deciding on a next step.
If your main question is how ketamine-based care compares with other depression interventions, Sophroneo's blog guide to TMS vs Spravato vs ketamine vs ECT may be a useful companion read.
The insurance question
Insurance is often where esketamine and IV ketamine feel most different to patients. Spravato is more likely to have a coverage route when a patient meets clinical criteria, such as documentation of treatment-resistant depression and previous antidepressant trials. Prior authorization is still common, and approval is not automatic.
IV ketamine is often less likely to be covered for depression because it is commonly used off-label for this purpose. Patients may be asked to pay out of pocket, and the total cost can vary widely by provider, location, course length, and follow-up plan.
Before starting either option, ask practical questions:
• What diagnosis and treatment history are required?
• What will insurance cover, and what documentation is needed?
• How long is each visit, including monitoring?
• What side effects should be watched for?
• Who manages medication changes during and after treatment?
• What happens if symptoms improve, partially improve, or do not improve?
For a broader starting point, you can also review Sophroneo's services overview or learn what to expect during ketamine therapy for depression.
Which one is right for you?
There is no universal answer. If you have treatment-resistant depression and your insurance plan covers Spravato after authorization, esketamine may be the more accessible first option. If you have already tried Spravato without enough benefit, cannot access it, or are working with a clinician who recommends IV ketamine for specific clinical reasons, IV treatment may be worth discussing.
The safest approach is to speak with a psychiatrist who can review your full history and help you compare options honestly. For some people, the better next step is not ketamine at all, but a depression evaluation, medication adjustment, therapy referral, sleep treatment, or another evidence-informed plan.
If you are weighing ketamine-based care alongside other options, the Sophroneo comparison guide on ketamine vs TMS vs Spravato for depression can help you prepare better questions for a consultation.
Video context: esketamine for severe depression
This Mayo Clinic Minute video gives a brief clinical overview of esketamine for severe depression. Use it as background education, then discuss your own situation with a qualified clinician.
Frequently asked questions
Is esketamine the same thing as ketamine?
Not exactly. Esketamine is one specific form of ketamine, while standard IV ketamine usually includes a racemic mixture. In clinical practice, esketamine is used as a supervised nasal spray, while IV ketamine is delivered by infusion.
Does insurance cover ketamine infusions for depression?
Often, no. IV ketamine for depression is commonly off-label, so many insurers do not cover it. Spravato esketamine has a more formal coverage pathway for qualifying patients, though prior authorization and eligibility criteria still apply.
What does treatment-resistant depression mean for Spravato eligibility?
Treatment-resistant depression usually means symptoms have not improved enough after at least two adequate antidepressant trials. Exact requirements vary by insurer and clinical situation, so documentation matters.
Can I take Spravato at home?
No. Spravato is administered under supervision in a certified healthcare setting, and patients are monitored afterward. You should not drive on the day of treatment.
Is one treatment more effective than the other?
The evidence base and delivery method differ. Spravato has a formal approval pathway for specific depression indications. IV ketamine has significant clinical use and research support, but the decision should be individualized.
Ready to compare your options with a psychiatrist?
If you are comparing esketamine vs ketamine because depression has not improved enough, bring your medication history, prior diagnoses, insurance questions, and safety concerns into a structured consultation. A careful review can help you understand whether Spravato, IV ketamine, TMS, medication changes, therapy, or another approach belongs in your next step.
Comments